IP Library Granted Patent US 7,186,413
Granted Patent B2
US 7,186,413 · App. 10/445,026 · Granted Mar 6, 2007

Hydrogels and water soluble polymeric carriers for drug delivery

Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,186,413
App. No.
10/445,026
Granted
Mar 6, 2007
Kind
B2
Abstract

Carriers for drug delivery, methods of making such carriers and for associating them to drugs, the resulting carrier and drug combination and methods for drug delivery, particularly controlled or sustained release delivery, using such carrier and drug combinations.

Claims (13)

1. A water-soluble polymer/drug compound which comprises a water-soluble polymer bonded to a drug or prodrug by an in vivo degradeable covalent bond, wherein the bond is provided by a linking compound having two or more hydrazide groups which react with the polymer and drug to form separate hydrazone bonds to each of the polymer and the drug, and wherein the water-soluble polymer is a poly(vinyl alcohol), an alginate modified to convert at least a portion of its guluronate units to aldehyde guluronate units, a polyamine dendrimer, a poly(ethylene glycol) dendrimer, a poly(allyl amine), a poly(vinyl amine), a polyacrylamide or a polyalkyl(meth)acrylate, wherein the linking compound is adipic acid dihydrazide” after “polyalkyl(meth)acrylate.

2. The compound of claim 1 , wherein the drug, in its active form, has a ketone or aldehyde group which forms the hydrazone bond.

3. The compound of claim 1 , wherein the drug is a chemotherapy drug or the prodrug is a prodrug form of a chemotherapy drug.

4. The compound of claim 1 , wherein the drug is a growth factor or the prodrug is a prodrug form of a growth factor.

5. The compound of claim 1 , wherein the drug is a steroid or the prodrug is a prodrug form of a steroid.

6. The compound of claim 1 , wherein the drug is an anthracycline.

7. The compound of claim 1 , wherein the drug is mitoxanthrone or cisplatin.

8. A method for drug delivery which comprises administering to a patient a compound of claim 1 .

9. The method of claim 8 , wherein the compound is administered by injection.

10. The compound of claim 1 , wherein the drug is an taxol or taxotere.

11. The compound of claim 1 , wherein the drug is a bleomycin, mitomycin, or plicamycin or a platinum complex with amine groups.

12. The compound of claim 1 , wherein the polymer is a poly(vinyl alcohol).

13. The compound of claim 1 , wherein the polymer is an alginate modified to convert at least a portion of its guluronate units to aldehyde guluronate units.

Continuity (3)
Division 0983095500
Provisional Application 6010359500 · Oct 9, 1998
Related Publication 20040028745A1 · Feb 12, 2004